Pet in oncology i - lung, breast, soft tissue sarcoma

Nuclear Medicine Communications

Volumn 21, Issue 3, 2000, Pages 224-229

  O'DOHERTY M J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LUNG TUMOR; REVIEW; SARCOMA; SCINTISCANNING;

BREAST NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; RADIOPHARMACEUTICALS; SARCOMA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034152796     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200003000-00004     Document Type: Article

References (45)

1. Calman K, Hine D. A policy framework for commissioning cancer services: A report by the expert advisory group on cancer to the chief medical officers of England and Wales. London: Department of Health, 1995.
2. Gambhir SS, Barrio JR, Wu L et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 1998; 39: 2003-2011.
3. McCloud TC, Bourgouin PM, Greenberg RW et al. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT or correlative lymph node mapping and sampling. Radiology 1992; 182: 319-323.
4. Warburg O. The metabolism of tumors. New York: Richard R. Smith, 1931: 129-169.
5. 3H-2-deoxyglucose retention in murine tumour models. Nucl Med Biol 1996; 23: 533-541.
6. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Sem Nucl Med 1998; 28: 352-358.
7. Romer W, Hanauske A-R, Ziegler S et al. Positron emission tomography in non-Hodgkin’s lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
8. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-1312.
9. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30.
10. Boerner AR, Weckesser M, Herzog H et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26: 226-230.
11. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
12. Gambhir SS, Shepherd JE, Shah BD et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998; 16: 2113-2125.
13. Kubota K, Matsuzawa T, Fujiwara T et al. Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med 1990; 31: 1927-1933.
14. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation. Radiology 1994; 191: 371-377.
15. Dewan NA, Reeb SD, Gupta NC et al. PET FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: A comparative risk-benefit analysis. Chest 1995; 108: 441-446.
16. Slosman DO, Spiliopoulos A, Couson F et al. Satellite PET and lung cancer: A prospective study in surgical patients. Nucl Med Commun 1993; 14: 955-961.
17. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer: Approaching a controversy using meta-analysis. Am Rev Respir Dis 1990; 141: 1096-1101.
18. Gross B, Glazer G, Orringer M, Spizary D, Flint A. Bron-chogenic carcinoma metastatic to normal-sized lymph nodes: Frequency and significance. Radiology 1988; 166: 71-74.
19. Primack S, Lee K, Logan P. Bronchogenic carcinoma: Utility of CT in the evaluation of patients with suspected lesions. Radiology 1994; 193: 795-800.
20. White P, Adams H, Crane M, Butchart, E. Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumors? Thorax 1994; 49: 951-957.
21. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardio Thorac Surg 1994; 8: 37-42.
22. Webb WR, Gatsonis C, Zerhouni EA et al. CT and MR imaging in staging nonsmall cell bronchogenic carcinoma: Report of the radiologic diagnostic oncology group. Radiology 1991; 178: 705-713.
23. 18F]fluorodeoxyglucose. Ann Thorac Surg 1994; 58: 698-703.
24. Bury T, Dowlate A, Corhay JL et al. Whole body 18-FDG in the staging of non-small cell lung cancer. Eur Respir J 1997; 10: 2529-2534.
25. Valk PE, Pounds T, Hopkins D et al. Staging non-small cell lung cancer by whole body positron emission tomographic imaging. Ann Thorac Surg 1995; 60: 1573-1581.
26. Sazon DA, Santiago SM, Soo Hoo GW et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153: 417-421.
27. Boland GW, Goldberg MA, Lee MJ et al. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131-134.
28. Lewis P, Griffin S, Marsden P et al. Whole body 18F-fluoro-deoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
29. O’Reilly SM, Camplejohn RS, Barnes DM et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671-674.
30. Avril N, Dose J, Janiicke F et al. Assessment of axillary lymph node involvement in breast patients with positron emission tomography using radiolabelled 2-(fluorine-18)-fluoro-2-deoxy-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
31. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: A review. Cancer 1995; 76: 1491-1512.
32. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
33. Dehdashti F, Flanagan FL, Siegel BA. PET assessment of metabolic flare in advanced breast cancer. Radiology 1997; 205: 220.
34. Lawrence Jr W, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcoma: A pattern of care survey of the American College of Surgeons. Ann Surg 1996; 205: 349-359.
35. Enzinger FM, Weiss SW, eds. Soft tissue tumours, 3rd edn. St. Louis, MO: Mosby, 1995.
36. Adler LP, Blair HF, Williams RP et al. Grading liposarcomas with PET using [18F]FDG. J Comput Assist Tomogr 1990; 14: 960-962.
37. Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumours using PET. J Nucl Med 1991; 32: 1508-1512.
38. Griffin LK, Dehdashti F, McGuire AH et al. PET evaluation of soft tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-194.
39. Kern KA, Brunetti A, Chang AE et al. Metabolic imaging of human extremity musculoskeletal tumours by PET. J Nucl Med 1988; 29: 181-186.
40. Nieweg OE, Pruim J, Van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-261.
41. Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4: 1215-1220.
42. Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999; 26: 599-605.
43. Lucas JD, O’Doherty MJ, Wong JCH et al. Evaluation of the role of fluorodeoxyglucose positron emission tomography in the follow-up management of soft tissue sarcomas. J Bone Joint Surg 1998; 80B: 441-447.
44. Ahuja V, Coleman RE, Horndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-924.
45. Saunders CAB, Dussek J, O’Doherty MJ, Maisey MN. An evaluation of 18F-FDG whole body PET imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-797.